



November 24, 2008

Honorable Lois Capps
Congresswoman
1110 Longworth House Office Building
Washington, DC 20515

SUBJECT: H. R. 5629 “Pathway for Biosimilars Act”, H. R. 1956 “Patient Protection and Innovative Biologic Medicines Act of 2007”

Dear Congresswoman Capps,

The California Chamber of Commerce respectfully **REQUESTS YOUR SUPPORT** for **H. R. 5629** or **H. R. 1956** that would create a regulatory pathway for licensing of biosimilar biological products

CalChamber recognizes that licensing biosimilar biological products could significantly contribute to the goal of controlling health care costs, while promoting use of quality therapeutic alternatives. However, the manner by which we control cost and improve quality alternatives must adhere to the following principles: ability of the Food and Drug Administration to properly review and approve safe, pure and potent biosimilar biological products; safeguard successful discoveries with reliable patent and market exclusivity incentives; and encourage future innovation through a market competition-oriented business environment.

CalChamber looks forward to future debate on this legislation as it leads the U.S. closer to a market competition-based regulatory pathway for biosimilar biological products that prioritizes patient safety, sound science, good value to consumers, and innovator incentives. For these and other reasons, the California Chamber of Commerce **SUPPORTS H. R. 5629 and H. R. 1956** and urges your support.

Sincerely,

Marti Fisher
Policy Advocate

MF:fg